In short: Giroux: in the seven-name SMID-biotech takeout basket; the group also stands on its own — high-probability Phase 2/3 programs that could become $2–10B products.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.